Jennifer C. Deese, PhD, MPH, CCRPScientist
Areas of expertise
- HIV prevention
- Clinical trials design and implementation
Projects & Resources
This fact sheet summarizes the research agenda being implemented under Envision FP, a five-year contraceptive research award funded by the U.S. Agency for International Development.
Published Research/** * @file * Unformatted override for published research. * Using the same markup as "project" because it's the same */ ?>
Pre-exposure prophylaxis for HIV infection among African women
Van Damme L. Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, Malaheleha M, Owino F, Manongi R, Onyango J, Temu L, Monedi MC, Mak’Oketch P, Makanda M, Reblin I, Makatu SE, Saylor L, Kiernan H, Kirkendale S, Wong C, Grant R, Kashuba A, Nanda K, Mandala J, Fransen K, Deese J, Crucitti T, Mastro TD, Taylor D on behalf of the FEM-PrEP study group
New England Journal of Medicine. 2012; 367 (5): 411-22
Pre-exposure prophylaxis with antiretroviral drugs has been effective in the prevention of HIV infection in some trials but not in others. This randomized, double-blind, placebo-controlled trial assigned 2,120 HIV-negative women in Kenya, South Africa, and Tanzania to receive either a combination of tenofovir disoproxil fumarate and emtricitabine (TDF-FTC) or placebo once daily to assess the effectiveness of TDF-FTC in preventing HIV acquisition and to evaluate safety. The study was stopped early, on April 18, 2011, because of lack of efficacy. Prophylaxis with TDF-FTC did not significantly reduce the rate of HIV infection and was associated with increased rates of side effects, as compared with placebo. Despite substantial counseling efforts, drug adherence appeared to be low.
Injectable progestin-only contraception is associated with increased levels of pro-inflammatory cytokines in the female genital tract
Deese J, Masson L, Miller W, Cohen M, Morrison C, Wang M, Ahmed K, Agot K, Crucitti T, Abdellati S, Van Damme L.
Am J Reprod Immunol 2015 Oct; 74 (4): 357-67. [Journal Impact Factor: 2.438]
Contraceptive use of depot medroxyprogesterone acetate or norethisterone oenanthate was associated with increased inflammation in the female genital tract. Such inflammation is associated with increased HIV target cell availability and the likelihood of an increased risk of HIV acquisition, which is an ongoing concern for users of these contraceptives. The Evidence for Contraceptive Options and HIV Outcomes (ECHO) consortium is conducting a randomized clinical trial to define the role of hormonal contraception in HIV acquisition.
Sino-implant (II)® continuation and effect of concomitant tenofovir disoproxil fumarate-emtricitabine use on plasma levonorgestrel concentrations among women in Bondo, Kenya
Todd CS, Deese J, Wang M, Hubacher D, Steiner MJ, Otunga S, Van Damme L, Fem-PrEP study group.
Contraception 2014 Oct; epub ahead of print. [Journal Impact Factor: 2.932]
As oral pre-exposure prophylaxis becomes more widely available, understanding the interaction of Truvada with other commonly used pharmaceuticals will become more important. In particular, reproductive-aged women at high risk of HIV are in need of highly effective methods both to protect themselves against HIV and to prevent pregnancy. This paper provides early data on the effect of Truvada on levonogestrel levels among women using Truvada for HIV prevention and Sino-implant (II) for contraception.